well
establish
immunosuppress
see
terminolog
lead
increas
incid
andor
sever
infecti
neoplast
diseas
interpret
immunosuppress
data
experiment
immunotoxicolog
studi
even
epidemiolog
studi
use
quantit
risk
assess
problemat
mostli
due
pauciti
inform
health
consequ
minimaltomoder
immunosuppress
might
expect
occur
inadvert
exposur
immunotox
agent
human
import
scientif
sound
framework
establish
allow
accur
quantit
interpret
data
use
risk
assess
process
immunotoxicolog
may
requir
exampl
develop
model
equat
moder
chang
leukocyt
count
cell
number
andor
immunoglobulin
level
test
readili
perform
human
popul
potenti
chang
incid
sever
infecti
diseas
well
establish
social
econom
impact
incid
chang
although
experiment
anim
model
usual
provid
opportun
establish
reliabl
exposur
estim
conduct
inform
immun
test
conduct
human
extrapol
find
across
speci
alway
concern
develop
framework
perform
extrapol
current
address
author
workgroup
integr
process
undertak
review
studi
address
qualit
quantit
relationship
immun
paramet
diseas
contain
herein
initi
like
clinic
consequ
may
occur
result
chronic
mildtomoder
immunosuppress
describ
well
nonimmun
factor
may
modifi
diseas
outcom
clinic
experiment
anim
studi
examin
immunosuppress
diseas
relationship
review
quantit
relationship
avail
delin
help
address
gap
human
health
risk
assess
address
potenti
social
econom
consequ
could
result
immunotox
brief
descript
gener
impact
infecti
diseas
provid
paramet
comprehens
data
base
address
immunodefici
diseas
relationship
specif
primari
genet
immunodefici
aid
discuss
repres
extrem
exampl
immunosuppress
neither
specif
clinic
diseas
result
eventu
outcom
much
common
occur
individu
chronic
mildtomoder
immunosuppress
continu
use
provid
clarif
certain
terminolog
immunosuppress
immunodefici
immunocompromis
nonquantit
term
reflect
reduc
capac
immun
system
respond
antigen
term
often
use
interchang
immunotoxicolog
purpos
risk
assess
immunosuppress
defin
loss
abil
immun
system
respond
challeng
level
consid
normal
regardless
whether
clinic
diseas
ensu
immunodefici
often
repres
alter
immun
system
potenti
lead
clinic
diseas
whether
primari
ie
genet
etiolog
secondari
epigenet
natur
term
immunocompromis
like
immunosuppress
indic
defici
immun
respons
independ
whether
maladapt
immunotox
encompass
term
specifi
effect
immun
system
origin
xenobiot
exposur
immunotoxicolog
test
increasingli
includ
toxicolog
evalu
hous
ad
impetu
better
associ
detect
chang
test
potenti
clinic
outcom
although
infecti
diseas
obviou
consequ
maladapt
immun
affect
etiolog
progress
andor
sever
much
broader
rang
disord
includ
certain
cancer
autoimmun
diseas
establish
quantit
relationship
alter
immun
respons
frequenc
sever
diseas
human
popul
challeng
mani
factor
may
contribut
morri
potter
summar
schemat
figur
appear
progress
outcom
infecti
diseas
view
interrelationship
virul
organ
infecti
dose
number
organ
requir
produc
ill
integr
host
anatom
function
barrier
overal
immunocompet
individu
latter
affect
genet
well
age
gender
use
certain
medic
drugalcohol
use
smoke
histori
stress
nutrit
statu
factor
probabl
account
variabl
report
mean
immun
valu
exceed
two
standard
deviat
anoth
challeng
establish
quantit
associ
immun
function
diseas
account
function
overlap
ie
redund
exist
variou
immun
respons
diseas
multipl
effector
mechan
evok
respons
diseas
redund
often
misinterpret
reserv
howev
organsystem
liver
central
nervou
system
exist
immun
reserv
gener
popul
diseas
occur
uncompromis
individu
unlik
contrast
immun
redund
discuss
halloran
scientif
support
empir
examin
effect
redund
interpret
immunotoxicolog
studi
recent
address
keil
et
al
use
factor
analysi
multiplelogist
regress
quantit
evalu
contribut
differ
immun
system
paramet
host
resist
infecti
neoplast
diseas
associ
secondari
immunodefici
infecti
diseas
often
focu
epidemiolog
studi
neoplast
diseas
usual
long
latenc
period
particular
microorgan
respons
infect
may
assist
identifi
qualit
quantit
natur
immunodefici
exampl
extracellular
pathogen
streptococcu
pneumonia
haemophilu
influenza
multipli
outsid
phagocyt
cell
thu
produc
diseas
resist
phagocytosi
facult
intracellular
pathogen
eg
mycobacterium
tuberculosi
gener
phagocyt
resist
intracellular
kill
thu
infect
extracellular
facult
intracellular
organ
frequent
individu
impair
phagocyt
mechan
eg
neutropenia
humor
immun
defici
present
oblig
intracellular
pathogen
includ
virus
multipli
unless
within
host
cell
commonli
observ
individu
defect
cellular
immun
microbi
agent
associ
immunodefici
disord
also
classifi
common
opportunist
latent
pathogen
common
pathogen
occur
gener
popul
frequenc
associ
infecti
natur
eg
virul
eas
transmiss
repres
virus
caus
influenza
infect
sever
acut
respiratori
syndrom
sar
respiratori
system
vulner
target
common
pathogen
directli
expos
extern
environ
larg
surfac
area
four
time
combin
total
surfac
area
gastrointestin
tract
skin
gardner
upperrespiratori
infect
occur
age
group
produc
sever
effect
young
old
due
lesser
immunocompet
although
influenza
respons
morbid
mortal
infecti
agent
record
histori
patriarca
low
individu
rate
infect
gener
popul
one
two
episod
individu
per
year
combin
underreport
make
difficult
detect
chang
infect
rate
epidemiolog
studi
infect
common
pathogen
occur
routin
healthi
popul
opportunist
infect
typic
seen
individu
sever
immunosuppress
aid
patient
exampl
microorgan
produc
opportunist
infect
certain
protozoan
includ
toxoplasma
gondii
caus
cerebr
infect
intract
diarrhea
candida
albican
mycobacterium
avium
complex
mac
pneumocysti
carinii
fungu
caus
sever
lung
diseas
aid
patient
morri
potter
organ
commonli
encount
food
water
dust
soil
caus
diseas
gener
popul
low
incid
certain
pathogen
microorgan
respons
latent
infect
case
member
herp
viru
famili
includ
cytomegaloviru
cmv
herp
simplex
viru
hsv
epsteinbarr
viru
ebv
viru
remain
tissu
latent
form
follow
primari
infect
durat
host
life
healthi
individu
immun
system
maintain
viral
latenc
cellular
immun
play
major
role
cellular
immun
respons
compromis
viral
replic
ensu
potenti
caus
sever
complic
death
preced
viral
activ
vigor
immun
respons
viralspecif
antigen
occur
respons
replic
discuss
later
chang
virusspecif
immun
respons
activ
latent
virus
observ
individu
secondari
immunodefici
disord
mildtomoder
immunosuppress
may
exist
immunodefici
also
associ
increas
incid
certain
viral
induc
tumor
nonhodgkin
lymphoma
nhl
tumor
skin
penn
contrast
cancer
intern
organ
particular
lung
liver
often
induc
chemic
carcinogen
virusinduc
cancer
immunogen
thu
like
influenc
immunolog
factor
suppress
cellmedi
immun
associ
higher
incid
skin
cancer
leukemia
lymphoprolif
disord
transplant
patient
wherea
kaposi
sarcoma
ebvassoci
b
cell
lymphoma
associ
sever
immunosuppress
seen
patient
aid
natur
killer
nk
cell
like
play
role
resist
progress
metastat
spread
tumor
develop
rather
prevent
initi
herberman
unexpectedli
studi
individu
nk
cell
defici
state
associ
singl
gene
mutat
help
identifi
role
nk
cell
defens
human
infecti
diseas
resound
theme
nk
cell
defici
suscept
herp
virus
suggest
unexplain
sever
herp
viral
infect
rais
possibl
nk
cell
deficit
orang
mani
advantag
use
human
data
experiment
anim
studi
quantit
risk
assess
especi
avoid
difficulti
interspeci
extrapol
provid
data
lower
dose
interest
public
health
polici
maker
hertzpicciotto
human
studi
offer
realist
exposur
scenario
includ
multipl
rout
exposur
includ
much
divers
rang
genet
background
experiment
model
provid
potenti
explor
differ
suscept
genotyp
limit
challeng
human
studi
howev
consider
brief
overview
issu
surround
design
interpret
human
studi
pertain
assess
risk
due
immunotox
exposur
provid
design
human
studi
rang
control
clinic
trial
larg
populationbas
observ
studi
clinic
studi
offer
advantag
exposur
paramet
interest
often
control
eg
chamber
studi
inhal
toxic
challeng
studi
adenoviru
infect
outcom
prospect
monitor
also
disadvantag
ethic
consider
provid
littl
opportun
exposur
toxic
chemic
furthermor
studi
extens
biolog
monitor
function
immun
test
expens
exposur
well
outcom
interest
may
difficult
studi
avail
time
frame
studi
particip
typic
avail
longterm
exposur
extend
followup
purpos
obtain
data
immunotoxicolog
risk
assess
clinic
studi
particularli
use
provid
data
frequenc
infect
level
immun
respons
vaccin
variat
type
studi
design
might
includ
followup
patient
popul
administ
immunosuppress
therapi
ie
transplant
patient
describ
may
also
mani
characterist
observ
studi
type
human
studi
employ
immunotoxicolog
typic
classifi
observ
epidemiolog
observ
studi
vari
size
crosssect
one
point
time
retrospect
prospect
natur
design
advantag
disadvantag
initi
mean
control
observ
studi
introduc
studi
design
qualiti
valid
result
greatli
affect
method
use
select
studi
sampl
rigor
exposur
outcom
measur
addit
high
cost
observ
studi
challeng
mani
reason
includ
potenti
confound
host
age
gender
lifestyl
environment
frequenc
exposur
chemic
infecti
agent
factor
secondari
measur
control
observ
studi
use
multivari
analysi
techniqu
eg
regress
model
provid
suffici
sampl
size
inform
potenti
confound
overal
welldesign
epidemiolog
studi
eg
absenc
select
bia
exposur
outcom
misclassif
control
confound
factor
contribut
valuabl
inform
assess
risk
due
immunotox
exposur
exist
immunotoxicolog
studi
human
tend
base
upon
either
fairli
small
sampl
size
often
individu
transient
highlevel
occup
exposur
larg
group
chronic
lowlevel
exposur
although
instanc
bodi
burden
chemic
determin
draw
broadli
applic
conclus
studi
difficult
subject
may
expos
chemic
specif
address
studi
character
chemic
exposur
may
reli
subject
recal
rough
estim
durat
intens
exposur
furthermor
contrast
experiment
anim
function
assess
consider
difficult
human
requir
antigen
challeng
involv
risk
individu
studi
undertaken
subject
provid
commerci
vaccin
hepat
antigen
weisglaskuperu
et
al
van
loveren
et
al
yucesoy
et
al
sleijffer
et
al
cellular
humor
immun
respons
vaccin
thought
sensit
indic
immunosuppress
glaser
et
al
reflect
suscept
infecti
diseas
desedat
et
al
van
loveren
et
al
epidemiolog
studi
test
human
limit
blood
collect
peripher
cell
count
differenti
immunoglobulin
level
immunophenotyp
perform
certainli
valu
gener
agre
highli
sensit
indic
immunosuppress
make
difficult
detect
lowtomoder
level
immunosuppress
itc
need
extend
data
obtain
experiment
studi
human
recent
review
tryphona
howev
epidemiolog
data
effect
chemic
exposur
immun
paramet
infecti
outcom
human
popul
limit
complet
immunotoxicolog
studi
focus
persist
organochlorin
compound
formerli
found
pesticid
industri
chemicalseg
polychlorin
biphenyl
pcb
children
follow
prenat
perinat
exposur
via
matern
diet
breast
milk
accident
exposur
popul
japan
yusho
china
yucheng
suggest
associ
pcb
thermal
breakdown
product
quaterphenyl
polychlorin
dibenzofuran
found
contamin
rice
oil
immun
abnorm
increas
infect
children
born
expos
mother
yucheng
popul
lower
level
serum
iga
igm
higher
frequenc
respiratori
infect
otiti
media
compar
match
unexpos
control
lu
wu
nakanishi
et
al
yu
et
al
associ
pcb
increas
frequenc
otiti
media
children
also
describ
popul
studi
children
unit
state
michigan
show
gener
associ
organochlorin
level
preval
infect
posit
associ
polychlorin
biphenyl
pcb
dde
primari
metabolit
ddt
pcb
hexachlorobenzen
otiti
media
karmau
et
al
studi
inuit
infant
arctic
quebec
canada
dewailli
et
al
rel
risk
recurr
episod
least
three
per
year
otiti
media
higher
breastf
infant
second
third
highest
percentil
organochlorin
exposur
compar
lowest
three
month
age
breastf
infant
higher
exposur
level
lower
number
white
blood
cell
lymphocyt
lower
serum
iga
level
age
month
compar
bottlef
infant
dutch
preschool
children
weisglaskuperu
et
al
pcb
level
breast
milk
nonortho
planar
pcb
also
associ
increas
recurr
otiti
media
symptom
respiratori
infect
sampl
bodi
burden
pcb
age
month
associ
higher
preval
recurr
otiti
media
chicken
pox
pcb
bodi
burden
associ
differ
lymphocyt
marker
outsid
normal
rang
agematch
children
although
level
breast
milk
cord
blood
posit
correl
lymphocyt
count
variou
tcell
subset
find
link
otiti
media
pcb
exposur
consist
across
three
studi
possibl
determin
whether
chang
immun
paramet
mediat
associ
simpli
repres
parallel
find
immunotox
pesticid
follow
human
exposur
review
sever
author
thoma
et
al
vial
et
al
voccia
et
al
luebk
although
studi
describ
associ
pesticid
exposur
alter
immun
function
increas
rate
infect
sampl
size
gener
small
case
patient
selfselect
base
symptom
rather
exposur
furthermor
frequenc
infect
typic
estim
recal
sever
year
immun
function
data
scarc
studi
suffer
shortcom
exampl
rel
larg
n
welldefin
popul
live
around
aberdeen
north
carolina
near
pesticid
dump
site
prioriti
superfund
site
contain
organochlorin
pesticid
volatil
organ
compound
metal
evalu
immun
function
frequenc
viral
infect
compar
neighbor
commun
resid
aberdeen
age
found
higher
incid
herp
zoster
reactiv
herp
infect
caus
shingl
differ
frequenc
infecti
diseas
arndt
et
al
substudi
individu
live
aberdeen
significantli
higher
ageadjust
level
plasma
dde
live
neighbor
commun
furthermor
higher
level
plasma
dde
relat
lower
lymphocyt
respons
mitogen
higher
absolut
lymphocyt
count
iga
level
vine
et
al
separ
analysi
resid
live
nearer
pesticid
dump
site
lower
lymphocyt
respons
mitogen
stimul
greater
likelihood
lower
percentag
nk
cell
lower
limit
normal
refer
rang
vine
et
al
associ
seen
reactiv
herp
infect
plausibl
light
chang
given
nk
cell
play
import
role
gener
cytotox
tcell
requir
help
control
viral
infect
studi
illustr
sever
challeng
demonstr
effect
chemic
exposur
populationbas
set
although
infecti
outcom
zoster
associ
residenti
histori
chemic
exposur
aberdeen
suggest
immunosuppress
relat
proxim
dump
site
extens
expens
immun
marker
serum
indic
exposur
examin
small
subset
origin
sampl
thu
possibl
examin
potenti
pathway
lead
associ
zoster
human
data
pertain
effect
heavi
metal
solvent
lead
benzen
respect
much
come
occup
exposur
metal
eg
mercuri
cadmium
shown
immunotox
effect
mix
exposur
experienc
welder
expos
metal
fume
gase
recent
review
antonini
et
al
welder
may
experi
increas
suscept
pulmonari
infect
recurr
respiratori
infect
tuschl
et
al
possibl
due
decreas
nk
activ
cellmedi
immun
although
number
human
studi
evalu
immun
system
endpoint
occup
expos
cohort
immun
function
infecti
outcom
gener
report
cohort
well
establish
chronic
psycholog
factor
stressor
separ
divorc
caregiv
alzheim
patient
bereav
produc
lowtomoder
degre
immunosuppress
increas
infecti
diseas
incid
cohen
biondi
zannino
yang
glaser
kiecoltglas
et
al
exampl
studi
follow
member
famili
year
infect
four
time
like
occur
follow
familyrel
stress
event
stress
event
occur
meyer
haggerti
prospect
cohort
studi
individu
famili
follow
effect
famili
function
stress
incid
influenza
infect
clover
et
al
examin
week
influenza
epidem
end
show
infect
neg
associ
cohes
adapt
studi
human
challeng
infecti
agent
healthi
subject
assess
psycholog
stress
subsequ
administ
nasal
droplet
contain
respiratori
syncyti
viru
rsv
coronaviru
cohen
et
al
rate
respiratori
infect
p
clinic
cold
p
determin
virusspecif
antibodi
level
viral
isol
increas
doserespons
manner
increas
degre
psycholog
stress
fig
although
usual
conduct
small
cohort
immun
test
chronic
stress
individu
provid
insight
relationship
mildtomoder
immunosuppress
diseas
kiecoltglas
et
al
chronic
stress
group
show
increas
rate
infect
total
circul
cell
number
reduc
much
figur
rate
respiratori
infect
clinic
cold
determin
virusspecif
antibodi
level
viral
isol
follow
challeng
nasal
droplet
contain
respiratori
syncyti
viru
coronaviru
individu
demonstr
increas
psychologicalstress
indic
data
shown
observ
associ
associ
adjust
standard
control
variabl
n
adapt
cohen
et
al
control
valu
number
circul
b
cell
remain
unaffect
furthermor
ratio
usual
within
normal
report
rang
reduc
much
nk
cell
activ
control
valu
measur
mitogenstimul
lymphocyt
prolifer
although
gener
consid
sensit
indic
immun
function
reduc
stress
popul
control
valu
chang
within
rang
report
normal
valu
associ
chronic
stress
reactiv
latent
virus
cmv
ebv
measur
either
clinic
diseas
elev
specif
antibodi
titer
also
observ
kasl
et
al
glaser
et
al
glaser
et
al
esterl
et
al
cohen
biondi
zannino
yang
glaser
increas
specif
antibodi
titer
latent
virus
ie
seroconvers
reflect
viral
activ
replic
preced
diseas
onset
although
seroconvert
actual
develop
clinic
manifest
studi
also
conduct
examin
associ
psycholog
stress
immun
respons
follow
hepat
b
influenza
viru
pneumococc
vaccin
review
kiecoltglas
et
al
studi
student
defin
academ
stress
abil
seroconvert
follow
first
second
immun
hepat
b
vaccin
highli
associ
test
measur
stress
level
studi
involv
influenza
vaccin
alzheim
diseas
caregiv
respond
less
favor
vaccin
compar
control
show
increas
antibodi
titer
follow
immun
fourfold
increas
consid
adequ
respons
kiecoltglas
et
al
shown
figur
even
strike
effect
pneumococc
vaccin
respons
caregiv
signific
decreas
antibodi
titer
occur
current
caregiv
compar
control
period
follow
immunizationf
p
glaser
et
al
although
acut
stressor
like
chronic
stressor
also
moder
immunosuppress
larg
interindividu
differ
exist
due
variabl
stressinduc
sympathet
nervou
system
activ
observ
chang
shortliv
review
marsland
et
al
hematopoiet
stem
cell
transplant
hsct
came
gener
practic
employ
treatment
certain
hematolog
malign
aplast
anemia
inborn
genet
error
origin
hematopoiet
stem
cell
immunodefici
persist
well
year
follow
cell
graft
due
pregraft
radiat
treatment
manifest
decreas
primari
antibodi
respons
delay
hypersensit
respons
well
lower
cell
immunotoxicolog
figur
twentynin
patient
follow
day
preced
one
year
posttranspl
exam
cell
count
total
infect
score
includ
frequenc
sever
reprint
permiss
storek
et
al
number
serum
iga
level
och
et
al
thu
prospect
studi
provid
excel
model
help
identifi
quantit
relationship
immun
function
diseas
immun
system
undergo
recoveri
exclud
upperrespiratori
infect
seldom
monitor
allogen
bone
marrow
recipi
incid
infect
exce
first
year
postengraft
patient
three
infect
opportunist
infect
predomin
fungal
infect
common
follow
bacteria
viral
origin
och
et
al
atkinson
although
infect
occur
first
month
follow
transplant
like
due
defici
granulocyt
later
infect
appear
due
defici
cell
b
cell
prospect
studi
involv
transplant
patient
follow
day
postengraft
decreas
b
lymphocyt
well
total
mononuclear
cell
repres
strongest
associ
infecti
diseas
incid
p
storek
et
al
smaller
detail
studi
storek
et
al
evalu
patient
day
preced
posttranspl
exam
show
highli
signific
invers
correl
p
univari
analysi
cell
count
total
infect
score
ie
frequenc
sever
cell
number
b
cell
number
serum
immunoglobulin
level
delay
hypersensit
respons
fig
signific
associ
diseas
decreas
cell
count
primarili
depend
upon
activ
cell
rather
memori
cell
subpopul
compar
efficaci
allogen
marrow
transplant
blood
stem
cell
transplant
storek
et
al
demonstr
lower
rate
infect
blood
stem
cell
transplant
correspond
higher
high
memori
cell
higher
count
low
naiv
cell
studi
conduct
small
et
al
monitor
immun
cell
recoveri
follow
bone
marrow
cell
transplant
incid
infect
also
correl
cell
count
opportunist
infect
monitor
howev
almost
exclus
present
patient
consid
sever
immunosuppress
cell
count
cellsmm
relationship
cell
number
respiratori
viru
infect
examin
period
follow
transplant
small
group
tcell
deplet
use
antibodi
treatment
stem
cell
recipi
chakrabarti
et
al
relationship
cell
number
incid
respiratori
viru
infect
rel
linear
size
popul
small
howev
cell
experiment
group
progress
associ
chang
immun
system
clinic
diseas
cellsmm
compar
cellsmm
found
control
group
although
well
studi
hsct
patient
also
manifest
defici
humoralmedi
immun
presum
due
insuffici
cell
help
rather
direct
b
cell
deficit
respect
sheridan
et
al
studi
leukemia
patient
allogen
bone
marrow
transplant
note
high
incid
pneumococc
infect
specif
associ
lowtoabs
level
detect
serum
level
studi
organ
transplant
patient
particularli
renal
also
provid
insight
longterm
consequ
moder
immunosuppress
immunosuppress
therapi
greatli
improv
past
year
transplant
patient
still
predispos
high
rate
malign
infect
infect
rate
rang
first
month
posttransplant
cmv
repres
report
infect
sia
paya
advent
longterm
monitor
increas
incid
cancer
also
note
popul
exampl
risk
develop
skin
tumor
follow
renal
transplant
year
year
incid
squamou
cell
carcinoma
higher
basal
cell
carcinoma
higher
gener
popul
hartevelt
et
al
initi
immunosuppress
therapi
renal
transplant
consist
gener
combin
cyclosporin
csa
azathioprin
steroid
cocktail
therapi
subsequ
reduc
adjust
base
upon
time
follow
transplant
evid
acut
reject
evid
toxic
usual
serum
creatinin
level
white
blood
cell
count
latter
maintain
cellsmm
jamil
et
al
examin
renal
transplant
patient
show
risk
lymphoma
infect
first
month
posttransplant
increas
proport
level
immunosuppress
therapi
rang
urinari
tract
infect
associ
transplant
common
type
infect
group
sever
bacteri
infect
pneumonia
septicemia
systemicinvas
fungal
infect
almost
exclus
associ
intens
immunosuppress
therapi
high
incid
cmv
antibodi
occur
three
group
seroconvert
base
upon
level
immunosuppress
therapi
contrast
infecti
diseas
fewer
case
squamou
basal
cell
carcinoma
aggress
treat
group
compar
group
probabl
due
antiprolif
effect
therapeut
wienek
et
al
also
examin
renal
transplant
patient
demonstr
reduc
subclass
level
cell
count
best
predictor
infect
rel
risk
increas
patient
normal
valu
lower
valu
clark
et
al
follow
small
cohort
patient
note
maintain
level
lymphocyt
least
cellsmm
reduct
number
seriou
viral
infect
occur
p
common
infecti
diseas
occur
often
usual
sever
young
case
agerel
physic
physiolog
differ
tissu
organ
respons
increas
suscept
infect
howev
case
rel
immatur
immun
system
young
prevent
host
make
adequ
respons
microorgan
neonat
particularli
suscept
infecti
agent
requir
adultlik
product
antibodi
complement
mediat
phagocytosi
bacteria
kill
includ
infect
encapsul
bacteria
eg
group
b
streptococcu
haemophilu
combin
low
express
level
innat
immun
function
lead
ineffici
bacteri
kill
subsequ
develop
infect
laboratori
studi
provid
qualit
quantit
inform
differ
immun
function
predispos
neonat
young
children
infect
bacteria
commonli
associ
neonat
sepsi
infect
gram
neg
e
coli
initi
control
polymorphonuclear
leukocyt
pmn
first
cell
arriv
site
infect
tissu
damag
pmn
newborn
produc
lower
rate
adult
wilson
produc
approxim
half
lysozym
lactoferrin
level
adult
cell
ambruso
et
al
adult
content
immunotoxicolog
bactericidalpermeabilityincreas
protein
import
destroy
microorgan
levi
et
al
recoveri
infect
involv
opson
bacteria
antibodi
complement
birth
neonat
nearli
total
adult
immunoglobulin
ig
level
adult
igg
level
although
signific
portion
maternallyderiv
form
passiv
protect
wane
matern
antibodi
catabol
month
age
infant
adult
ig
level
stiehm
fudenberg
antibodi
synthesi
progress
slowli
age
still
adult
level
year
age
stiehm
fudenberg
wolach
et
al
report
serum
preterm
infant
newborn
also
adult
level
complement
activ
main
opson
complement
compon
although
neonat
higher
percentag
total
lymphocyt
circul
compar
adult
thymusderiv
lymphocyt
immatur
compar
adult
ciccimarra
immatur
cell
incap
make
cytokin
critic
mount
effect
immun
respons
gener
longliv
memori
cell
phenotyp
analys
cord
neonat
adult
peripher
blood
also
shown
differ
cell
subpopul
tabl
well
differ
balanc
cytokin
product
birth
respons
skew
favor
cell
respons
upham
et
al
presum
decreas
effici
hostprotect
respons
particularli
intracellular
bacteria
increas
risk
develop
allerg
asthma
similar
agerel
defect
immun
function
may
also
predispos
factor
repeat
inner
ear
infect
young
children
faden
note
children
experi
four
inner
ear
infect
within
first
year
life
particularli
h
influenza
igg
antibodi
respons
conserv
bacteri
capsular
protein
increas
year
age
infectionpron
group
cell
respons
antigen
also
reduc
suggest
repeat
infect
may
caus
subtl
immunolog
abnorm
suscept
children
immun
system
elderli
character
gradual
declin
function
immunosenesc
addit
underli
chronic
diseas
diabet
emphysema
burn
goodwin
result
increas
incid
sever
infect
common
pathogen
adult
year
age
pneumonia
influenza
togeth
fourth
lead
caus
death
yoshikawa
although
immun
effect
popul
basi
cdc
estim
excess
death
year
influenza
occur
individu
year
old
due
part
poor
vaccin
respons
fukuda
et
al
neonat
immun
system
character
immatur
cell
immun
system
elderli
character
normal
number
matur
cell
declin
abil
respond
imunogen
shou
et
al
wayn
et
al
increas
rate
sever
infect
occur
elderli
product
effect
well
physiolog
chang
associ
age
process
physic
effect
includ
ineffici
bladder
function
decreas
clearanc
lung
secret
reduc
gastric
acid
gavazzi
kraus
culmin
reduc
barrier
clearanc
function
normal
reduc
bacteri
load
organ
variou
degre
malnutrit
micronutri
defici
also
common
elderli
contribut
decreas
resist
lesourd
although
rel
distribut
immun
cell
chang
dramat
elderli
chang
rel
abund
certain
cell
subpopul
occur
loss
cell
secondari
thymic
involut
appear
third
decad
life
cell
predomin
circul
young
adult
rel
distribut
elderli
shift
toward
increas
proport
memori
cell
exampl
lesourd
report
decreas
cell
count
increas
cell
popul
averag
age
year
compar
year
old
tabl
despit
increas
popul
specif
educ
memori
cell
mani
cell
respond
poorli
presum
reach
replic
limit
effro
pawelec
pattern
cytokin
product
also
chang
age
although
contradictori
result
obtain
human
studi
cakman
et
al
report
product
reduc
product
increas
elderli
compar
year
old
may
part
explain
reduc
cellmedi
resist
influenza
infect
elderli
although
total
number
circul
b
cell
chang
age
b
cell
respons
also
compromis
elderli
weksler
immun
diphtheria
toxin
younger
subject
produc
higher
antibodi
titer
persist
longer
titer
older
subject
evalu
singl
cell
level
plasma
cell
younger
subject
plenti
produc
antibodi
per
cell
basi
elderli
burn
et
al
addit
function
chang
cellular
humor
immun
innat
immun
suppress
elderli
includ
pmn
function
result
reduc
superoxid
product
shorter
halfliv
lord
et
al
rel
difficult
determin
contribut
chronic
lowlevel
immunosuppress
cumul
effect
immunotoxicolog
selgrad
et
al
burleson
van
loveren
bradley
b
abbrevi
cfu
coloni
form
unit
modest
chang
immun
function
background
incid
diseas
human
popul
sever
effort
made
examin
relationship
experiment
group
field
immunotoxicolog
set
test
usual
refer
host
resist
assay
evolv
group
experiment
anim
challeng
either
infecti
agent
transplant
tumor
challeng
level
suffici
produc
either
low
incid
minim
infect
control
group
tabl
endpoint
test
evolv
rel
nonspecif
eg
anim
morbid
mortal
continu
measur
tumor
number
viral
titer
bacteri
cell
count
sensit
model
increas
although
still
limit
number
anim
realist
devot
laboratori
studi
interanim
variabl
consider
effort
establish
interlaboratori
variabl
robust
test
measur
specif
endpoint
antibodi
respons
templ
et
al
histopatholog
icici
kuper
et
al
quantit
cell
surfac
marker
flow
cytometri
burchiel
et
al
zenger
et
al
cytokin
product
langeza
et
al
hermann
et
al
two
effort
evalu
sensit
predict
valu
individu
measur
immun
outcom
host
resist
test
auspic
us
nation
toxicolog
program
ntp
panel
expert
gather
priorit
list
immunolog
host
resist
assay
would
suitabl
use
mous
studi
formal
valid
initi
luster
et
al
smaller
effort
undertaken
nation
institut
public
health
environ
rivm
focus
rat
base
oecd
guidelin
vo
vo
van
loveren
vo
program
host
resist
test
usual
consid
second
third
test
level
tier
evalu
perform
indic
alter
immun
function
first
second
tier
data
subsequ
obtain
valid
program
indic
host
resist
assay
correl
immun
test
sensit
mani
function
test
recent
review
germolec
sever
studi
address
individu
relationship
chang
immun
measur
host
resist
test
routin
use
rodent
studi
rare
singl
compon
immun
system
sole
respons
resist
specif
infecti
agent
tumor
type
certain
immun
measur
show
signific
correl
outcom
individu
host
resist
assay
exampl
reduct
nk
cell
activ
correl
increas
suscept
challeng
sarcoma
cell
melanoma
cell
murin
cmv
luster
et
al
selgrad
et
al
suppress
cellmedi
immun
complement
defici
depress
macrophag
neutrophil
function
associ
decreas
resist
listeria
monocytogen
petit
luster
et
al
bradley
humor
compon
decreas
resist
shown
follow
depress
arm
immun
system
luebk
van
loveren
et
al
predict
valu
individu
immun
test
host
resist
shown
rang
rel
good
plaqu
form
cell
assay
nk
cell
activ
delay
type
hypersensit
respons
poor
lymphoprolif
respons
lp
combin
sever
immun
test
allow
high
concord
luster
et
al
indic
two
three
specif
test
requir
screen
adequ
immunotox
delet
function
block
specif
immun
compon
experiment
anim
use
elucid
rel
contribut
specif
molecul
signal
pathway
cell
diseas
resist
hickmandavi
achiev
via
target
gene
disrupt
result
anim
defici
specif
cell
popul
solubl
mediat
contribut
host
defens
eg
cell
knockout
treatment
normal
anim
select
toxic
agent
eg
use
gadolinium
chlorid
block
macrophag
function
administr
neutral
antibodi
critic
cellspecif
surfac
receptor
studi
wilson
et
al
specif
design
determin
magnitud
nk
cell
suppress
would
translat
alter
resist
three
diseas
model
studi
conduct
nk
cell
deplet
antibodi
cell
surfac
molecul
asialo
use
treatment
regimen
alter
standard
immun
function
test
use
assess
immunotox
rodent
author
demonstr
low
level
tumor
challeng
approxim
reduct
nk
cell
activ
thought
involv
primarili
metastat
process
requir
signific
effect
resist
nksensit
tumor
could
observ
studi
also
demonstr
level
suppress
need
alter
host
resist
relat
challeng
level
tumor
convers
studi
use
monoclon
antibodi
effect
deplet
lymphocyt
found
littl
evid
alter
resist
challeng
sarcoma
cell
model
thought
depend
cellmedi
immun
weaver
et
al
studi
design
address
contribut
singl
immun
paramet
host
resist
limit
studi
design
specif
address
limit
keil
et
al
demonstr
monitor
sever
immunolog
paramet
concurr
provid
inform
might
evid
studi
use
singl
test
use
prototyp
immunosuppress
agent
dexamethason
author
demonstr
contrari
would
expect
base
compound
suppress
effect
cytokin
product
cell
function
nk
cell
activ
rel
high
level
dexamethason
need
decreas
resist
listeria
monocytogen
dose
suppress
mani
immun
paramet
increas
neutrophil
number
nitrit
product
periton
macrophag
observ
suggest
lower
dose
dexamethason
signific
increas
concentr
neutrophil
blood
conjunct
increas
product
nitric
oxid
compens
decrement
immun
paramet
overal
resist
pathogen
compromis
keil
et
al
heryzk
et
al
develop
test
paradigm
evalu
immun
function
within
context
resist
specif
infect
follow
infect
candida
albican
fourparamet
model
use
includ
surviv
spleen
coloni
form
unit
cfu
muscl
cfu
antibodi
titer
author
suggest
allow
inclus
evalu
nonspecif
cell
humoralmedi
immun
respons
approach
prove
success
identifi
immunosuppress
immunostimulatori
compound
advantag
abl
evalu
multipl
immun
endpoint
intact
anim
directli
relat
clinic
endpoint
util
method
screen
tool
yet
evalu
use
larg
number
test
articl
environment
chemic
procedur
wide
use
outsid
pharmaceut
industri
variabl
virul
dose
infecti
agent
impact
abil
clear
infect
human
control
experiment
anim
model
use
group
mice
receiv
increas
dose
immunsuppress
agent
luster
et
al
challeng
mice
increas
dose
immunotoxicolog
tumor
cell
order
help
clarifi
doserespons
relationship
observ
even
immunolog
normal
anim
provid
suffici
number
tumor
cell
develop
high
frequenc
tumor
number
tumor
cell
requir
produc
tumor
decreas
proport
degre
immunosuppress
interpret
indic
immun
functiondiseas
respons
relationship
tend
linear
natur
rather
threshold
although
possibl
confirm
relationship
human
suggest
similar
respons
relationship
would
also
applic
human
albeit
differ
slope
provid
modifi
present
similar
relationship
suggest
studi
mice
treat
cyclosporin
challeng
group
b
streptococcu
although
studi
use
l
monocytogen
challeng
indic
doserespons
curv
would
affect
composit
effect
immun
paramet
keil
et
al
major
purpos
undertak
immuntoxicolog
studi
whether
anim
model
clinic
studi
identifi
potenti
hazard
ultim
assist
risk
assessmentmanag
process
decis
process
take
account
social
econom
impact
potenti
health
effect
would
ensu
order
begin
establish
framework
incorpor
immunotoxicolog
data
risk
assessmentmanag
process
necessari
identifi
social
econom
impact
infecti
diseas
gener
popul
precis
inform
readili
avail
sever
sourc
indic
signific
even
small
chang
infecti
diseas
frequenc
major
impact
impact
associ
mortal
lesser
extent
morbid
common
pathogen
influenza
pneumonia
determin
serv
basi
risk
manag
process
death
costli
impact
societi
ageadjust
death
rate
influenza
pneumonia
per
respect
base
th
revis
intern
statist
classif
diseas
relat
health
problem
th
revis
code
togeth
infect
rank
seventh
lead
caus
death
us
age
anderson
mortal
rate
infant
influenza
pneumonia
death
per
live
birth
declin
hoyert
et
al
minino
et
al
year
number
domin
pneumonia
condit
secondarili
relat
ill
disord
relat
low
birth
weight
respiratori
distress
bacteri
sepsi
account
higher
infant
death
minino
et
al
includ
neonat
day
age
howev
influenza
pneumonia
still
rank
seventh
post
neonat
anderson
year
age
group
chronic
lower
respiratori
diseas
influenzapneumonia
fourth
fifth
rank
lead
caus
death
respect
anderson
howev
pneumon
due
aspir
solid
liquid
lung
becom
common
caus
death
among
elderli
rank
fifteenth
lead
caus
death
minino
et
al
econom
impact
result
infecti
diseas
captur
determin
number
death
hospit
outpati
emerg
room
visit
specif
ill
usual
collect
nation
survey
appli
formula
convert
dollar
cost
ill
methodolog
handl
degre
confid
valu
medic
cost
product
loss
attempt
captur
burden
infecti
diseas
mortal
morbid
note
howev
estim
burden
account
reduc
function
abil
loss
pain
suffer
cost
individu
famili
member
cowork
psycholog
emot
stress
mani
fundament
unobserv
quantiti
valu
output
lost
result
employe
infecti
diseas
episod
valu
lost
work
day
explain
entir
product
loss
provid
comparison
indic
nihsponsor
effort
use
method
previou
diseasespecif
result
estim
cost
appli
inflat
factor
time
period
consider
estim
total
cost
influenza
pneumonia
amount
includ
billion
medic
cost
billion
product
loss
leigh
et
al
kirstein
langley
et
al
estim
annual
cost
rsv
infect
million
use
code
children
younger
year
age
largest
cost
associ
hospit
servic
infect
children
requir
admiss
averag
medic
care
expenditur
children
year
age
younger
per
child
toxic
agent
adequ
clinic
data
ie
exposur
level
diseas
incid
rare
avail
accur
determin
safe
exposur
level
without
need
includ
observ
either
experiment
model
human
biomark
studi
thu
import
scientif
sound
framework
establish
allow
accur
quantit
interpret
experiment
biomark
data
risk
assess
process
immunotoxicolog
data
may
requir
exampl
develop
model
equat
chang
leukocyt
count
cell
number
andor
immunoglobulin
level
readili
perform
human
chang
background
incid
sever
infecti
diseas
although
experiment
anim
model
provid
opportun
perform
inform
immun
test
establish
reliabl
exposur
estim
extrapol
find
across
speci
also
introduc
consider
uncertainti
review
provid
specif
framework
perform
extrapol
author
attempt
provid
background
inform
qualit
quantit
relationship
immun
paramet
diseas
would
integr
effort
follow
gener
conclus
surmis
major
clinic
least
readili
discern
consequ
mildtomoder
chronic
immunosuppress
increas
incid
infecti
diseas
studi
address
infecti
diseas
sever
neoplast
diseas
addit
immunosuppress
mani
nonimmun
factor
affect
infecti
diseas
incid
consid
data
interpret
particularli
evid
infect
common
pathogen
influenza
pneumonia
young
elderli
type
infecti
diseas
observ
often
depend
upon
specif
arm
immun
system
affect
thu
increas
infect
oblig
intracellular
pathogen
viral
infect
like
occur
follow
suppress
cell
mediat
immun
defect
phagocyt
activ
neutropenia
like
increas
suscept
facult
intracellular
microb
increas
infecti
diseas
incid
follow
chronic
immunosuppress
caus
common
pathogen
opportunist
microb
activ
latent
virus
often
herp
famili
abil
detect
chang
frequenc
infect
common
pathogen
epidemiolog
studi
eg
increas
respiratori
infect
influenza
prove
difficult
like
due
requir
complex
studi
design
increas
incid
infect
opportunist
microb
readili
observ
individu
sever
immunodefici
aid
immunolog
paramet
especi
cell
number
reduc
control
valu
consider
difficult
ascertain
health
consequ
lowtomoder
level
immunosuppress
would
like
occur
exposur
immunotox
agent
sever
immunosuppress
number
studi
howev
indic
popul
increas
risk
infect
common
pathogen
latent
virus
particularli
herp
famili
opportunist
infect
insuffici
clinic
data
determin
whether
relationship
decreas
immun
respons
increas
infecti
diseas
follow
linear
threshold
relationship
human
studi
experiment
anim
model
howev
support
linear
relationship
immunotoxicolog
multipl
immun
system
paramet
affect
howev
threshold
relationship
occur
singl
immun
paramet
eg
nk
cell
activ
target
differ
may
associ
redund
immun
system
major
gap
clarifi
shape
doserespons
curv
immun
respons
chang
diseas
risk
lack
largescal
epidemiolog
studi
popul
mildtomoder
immunodefici
monitor
simultan
immun
system
paramet
clinic
diseas
larg
studi
previous
undertaken
limit
valu
exampl
assess
immun
relationship
patient
aidsdefin
ill
pnuemocycti
carinii
pneumonia
pcp
cmv
mycobaterium
avium
complex
mac
multicohort
aid
center
limit
individu
cell
count
liter
pauli
kopferschmittkubl
margolick
et
al
amornkul
et
al
interestingli
cumul
probabl
aid
infecti
diseas
death
latter
stage
show
rel
linear
respons
occurr
patient
cell
count
liter
liter
respect
vlahov
et
al
furthermor
one
studi
patient
fail
meet
studi
criteria
cell
count
liter
develop
pcp
four
develop
cmv
three
develop
mac
indic
opportunist
infect
occur
less
immunosuppress
individu
lower
incid
lyle
et
al
review
prepar
conjuct
immunotoxicolog
workgroup
sponsor
us
environment
protect
agenc
epa
offic
research
develop
nation
center
environment
assess
epa
offic
children
health
protect
nation
institut
environment
health
scienc
nation
toxicolog
program
nation
institut
occup
safeti
health
health
effect
laboratori
divis
member
workgroup
includ
author
dr
david
chen
epaocph
marquea
king
epaordncea
yung
yang
epa
oppt
special
thank
dr
bob
sonawan
epaordncea
help
organ
effort
report
review
us
environment
protect
agenc
offic
research
develop
approv
public
approv
signifi
content
reflect
view
agenc
ambruso
dr
bentwood
b
henson
pm
johnston
rb
jr
oxid
metabol
cord
blood
neutrophil
relationship
content
degranul
cytoplasm
granul
pediatr
re
amornkul
pn
tansuphasawadikul
limpakarnjanarat
k
likanonsakul
young
n
eampokalap
b
kaewkungw
j
naiwatanakul
von
bargen
j
hu
dj
mastro
td
clinic
diseas
associ
subtyp
b
e
infect
among
patient
thailand
aid
